GlassScriptPhysician profile
Efrem Michael Cox
NPI 1841581527
$44,701.94
in general payments reported to CMS, 2019-2025
27 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $4,852 · 2021: $9,709 · 2022: $18K · 2023: $3,567 · 2024: $4,556 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,526 · Travel and Lodging: $1,987 · Consulting Fee: $900 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,525.82 |
| Travel and Lodging | $1,986.87 |
| Consulting Fee | $900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $25,128.33 | 2020-2025 | Monterey Al, Mako, Everest Spinal System |
| Depuy Synthes Sales INC. | $6,042.84 | 2019-2025 | Teligen, Viper, Velys |
| Globus Medical, INC. | $3,202.48 | 2019-2024 | Excelsiusgps Robotic Navigation System |
| Providence Medical Technology, INC. | $2,587.93 | 2022-2025 | |
| Medical Device Business Services, INC. | $2,436.27 | 2021-2023 | Conduit |
| Nuvasive, INC. | $894.73 | 2020-2022 | |
| Spineology INC. | $628.71 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $589.40 | 2019-2022 | |
| Icotec Medical INC. | $485.49 | 2023-2024 | Vader Pedicle System, Icotec Blackarmor Spine System |
| Kls-Martin L.P. | $392.73 | 2020-2022 | |
| Medtronic USA, INC. | $364.78 | 2019-2020 | |
| Aesculap, INC. | $315.98 | 2024-2025 | Gav, Progav 2.0 |
| Nevro Corp. | $218.84 | 2021 | |
| Integrity Implants INC. Dba Accelus | $209.66 | 2024 | |
| Si-Bone, INC. | $204.35 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $186.21 | 2020-2022 | |
| Biotronik Nro, INC. | $175.08 | 2023-2024 | Biotronik, Prospera |
| Irras USA, INC. | $146.25 | 2020 | |
| Arthrex, INC. | $131.92 | 2024 | |
| Spineart USA INC | $128.98 | 2023 | Cure Acp |
| Medtronic, INC. | $67.60 | 2023-2024 | Kyphon Express II Kyphopak Tray, Mazor X System, Strata |
| Integra Lifesciences Corporation | $59.85 | 2022 | |
| Goode Surgical INC | $38.40 | 2024 | |
| Livanova USA, INC. | $25.46 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $19.00 | 2025 | General - Pain Management |
| Abbott Laboratories | $14.85 | 2024 | Penta |
| Biocomposites INC | $5.82 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrem Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.